Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies that produce the lion's share of industry revenues.

Buy your copy of this report @ http://www.reportsnreports.com/reports/190914-pharmaceutical-products-of-the-future-50-company-biopharma-and-traditional-pipeline-analysis-to-2016.html

Report Details:
Published: August 2012
No. of Pages: 220
Price:Single User License:US$2500 Corporate User License:US$5000



Coverage of the 50 Leading Companies


This report takes a look at the pipeline of the following companies. The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:
Abbott Laboratories
Actelion
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen IDEC
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corp.
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly & Co.
Forest
Gilead Sciences
GlaxoSmithKline
Grifols SA
Hospira
Johnson & Johnson
Kyowa Kirin
Lundbeck
Menarini
Merck
Merck KGaA
Mitsubishi Tanabe Pharma
Mylan
Novartis
Novo Nordisk
Ono Pharmaceutical Co.
Otsuka Pharmaceutical
Pfizer
Purdue Pharma
Reckitt Benckiser
Roche
Sanofi
Santen Pharmaceuticals
Servier
Shionogi
Shire
Taisho Pharmacueitcal
Takeda
TEVA
UCB
Valeant Pharmaceuticals
Warner Chilcott
Watson

While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Pipeline Analysis, Key Trends, Market Forecasts



This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.

As part of its coverage, the report provides the following:
Company Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
The Traditional Pharmaceutical Market
Biotechnology Market Facts and Forecast

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.

The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders. Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.

Issues and Trends discussed in this report include:
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Biosimilar Development
Aging Populations
Mergers, Acquisitions, and Collaborations
Contributors to R&D Success
R&D Spending Trends
The Role of Contract Research Organizations
Sustainability in a Changing Pharmaceutical Industry

2011-2015 Global MEMS Accelerometer Market

TechNavio’s analysts forecast the Global MEMS Accelerometer market to grow at a CAGR of 17.5 percent over the period 2011–2015. One of the key factors contributing to this market growth is the declining price of MEMS accelerometers. The Global MEMS Accelerometer market has also been witnessing an increasing number of MEMS accelerometer applications in safeguarding laptop hard disks. However, the high cost of production could pose a challenge to the growth of this market.

TechNavio’s report, the Global MEMS Accelerometer Market 2011–2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global MEMS Accelerometer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

MEMS Accelerometer Market

Published: March 2012
No. of Pages: 33
Price: Single User License: US$ 1500     Corporate User License: US$2500

 

Key questions answered in this report:

* What will the market size be in 2015 and at what rate will it grow?
* What key trends is this market subject to?
* What is driving this market?
* What are the challenges to market growth?
* Who are the key vendors in this market space?
* What are the opportunities and threats faced by each of these key vendors?
* What are the strengths and weaknesses of each of these key vendors?

Few points from Table of Contents
Table Of contents

01. Executive Summary

02. Introduction

03. Market Coverage

04. Market Landscape

05. Geographical Segmentation

06. Vendor Landscape

07. Buying Criteria

08. Market Growth Drivers

09. Drivers and their Impact

10. Market Challenges

11. Impact of Drivers and Challenges

12. Market Trends

13. Key Vendor Analysis
13.1 STMicroelectronics N.V
13.2 Bosch Sensortec GmbH
13.3 Kionix Inc.
13.4 Freescale Semiconductor Inc.

The Outlook for Pharmaceuticals Worldwide

Espicom’s Pharmaceutical Market Outlook reports have been used by senior management in commerce and industry for 30 years. Why? Because our experienced team of researchers and analysts combine economic, scientific, demographic and language skills to produce an unmatched and critical evaluation of the operating environment for pharmaceutical companies.

An unmatched level of intelligence sourcing

Our full time team of experts regularly access over 1,200 primary source information points in regulatory authorities, health organisations, statistics offices and industry. Much of the information in the Pharmaceutical Market Outlook reports is not readily available in English elsewhere. Espicom partners with the widely regarded Economist Intelligence Unit (EIU) to provide up-to-date economic data – a constant requirement in these rapidly changing times.

Detailed analysis & novel forecasts

Assembling comprehensive data is one thing, but our strength lies in its interpretation. What does it mean and what are the implications for operations and business development? Our analysis is second to none and the economic and market forecasts are built on solid research principles and continually assessed to reflect current and anticipated market conditions.

Worldwide Pharmaceuticals Outlook Market

Published: March 2012
Price: US$ 17490             

Global industry...

By 2016, the global pharmaceutical market, including pharmacy and hospital sales, is forecast to be worth around US$1.6 trillion at retail prices. High growth in emerging markets will leverage slow growth in developed markets. Cost-containment policies will be offset against market demands for more effective products. Health access will expand, due to increasing generic penetration.

Localisation
The local market is the operating environment in which companies have to work. Domestic priorities set the agenda that affects a company’s operations, therefore the prevailing macroenvironment needs to be both understood and planned for. In this way, pharmaceutical companies have strengthened their capabilities to increase sales in local and international markets.

Beyond BRIC markets

The USA will continue to be the first worldwide economy, but other emerging markets will perform well, led by China, India, Russia and Brazil. However, a second wave of emerging markets will arise, namely South Korea, Mexico, Turkey, Indonesia and Poland. In an environment that is becoming more regulated, pharmaceutical producers are re-aligning their global strategies.

Quality information = business confidence

Any investment in market information must make a real return in terms of market knowledge and business efficiency. That demands the data is of the highest quality, thoroughly researched with primary sources and with insightful analysis and forecasts. Our team of analysts – with science, language and analysis skills – work full time to produce pharmaceutical market information that is second to none. With Pharmaceutical Market Outlook you get comprehensive market evaluation on which you can rely.
Guaranteed.

Global Biosimilars: A return to optimism?

Examining the market for companies
The need for a settled market environment is essential if the growing numbers of biologic products losing patent protection in the next 5-10 years is to be exploited. However, progress is painfully slow and critical issues driving the market dynamic include:

Industry investment: a sign of confidence?
This report provides a detailed analysis of 50 companies active in the biosimilars field, many of which have declared their interest in 2011. The move may reflect a growing confidence that as regulatory provision for biosimilars increases, and as the pipeline of prospective products matures, then the prospect of actually being able to launch products grows more realistic.

The US continues to disappoint; Europe forges ahead
Despite President Obama's health reform bill being passed in 2010, very little has happened. And the FDA's cautious approach suggests little will happen in the immediate future. The much anticipated Guidance, expected in 2011 has failed to appear, and in May 2011 FDA published details for User Fees - a scheme that will not come into effect (assuming it is passed by Congress) until 2013. Given that an untried regulatory system will not operate at the fastest speed then prospects of a US market for advanced biosimilars seem remote before 2015. In contrast, European regulators are revising their widely-adopted regulations in the light of experience, with a view to issuing revisions and guidance in 2012.

Developing markets may offer a profitable alternative
Developing markets with rising disposable incomes may present the medium-term prospect for biosimilars, since they combine a large target population with reduced operating costs. Many countries are following the EU model of regulation. Markets such as India and China have plenty of home-grown production capacity. Some companies have sought to turn this capacity to their advantage, and have signed deals with Chinese/Indian producers for the development of products to be sold around the world.

Global Biosimilars Market

Published:January 2012
No. of Pages: 200




The Challenge for Industry
The development of a biosimilar presents a series of challenges to traditional generic drug manufacturers seeking to enter the sector. To succeed, a company must have good financial backing. Small companies will be able to do the science, but the cost of product development and approval will generally exceed the resources of most chemical generic organisations. After this, there is the cost of marketing and post-market surveillance. There is little prospect in the EU and USA of biosimilars being sold unbranded and biosimilar developers will have to pay for the branding and the marketing of the products; a task for which many lack the funds, sales force and experience.

Corporate manoeuvring is seeing the competitive landscape change
Despite the challenges there has been an upsurge in company activity, most notably from the branded industry and from companies who have no current significant pharmaceutical interests. With the regulatory situation generally favourable to the branded industry, why are they interested?

There are three broad reasons why an originator would wish to become involved with biosimilars. Firstly, it would create a more diversified portfolio, an important consideration in an era of near-dry pipelines. Secondly, it would potentially allow for the development of expertise in the biologic area for companies which traditionally have limited involvement in biologics. Thirdly, it could potentially act as a "spoiler" operation by making the market environment more difficult for smaller biosimilar developers.

The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses now available at ReportsandReports

Dallas, TX: ReportsandReports announce The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses Market Research Report in its Store.

Browse complete The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses Report

The leading players in the Indian pharmaceutical market comprise both India-based and MNCs. This report provides an insight to the current state of Indian pharmaceutical industry as well as the evolving trends. This report analyzes the Indian pharmaceutical industry in light of market size, key drivers and resistors, trends and competitive positioning in the global market. It also analyzes the competitive landscape of the industry based on financial and operational (field force strength, R&D spend, exposure to chronic therapeutic areas and the US pharmaceutical market) parameters.

Table of Contents
Chapter 1 Introduction 20
What is this report about? 20
Methodology 20
Chapter 2 Industry overview 24
Summary 24
Introduction 25
Market dynamics 25
Indian pharmaceutical market: size and growth 25
Key market drivers and resistors 26
India’s adoption of product patent regime 27
Evolution of biopharmaceuticals in India 28
Competitive positioning of India in global pharmaceutical market 30
Competitive landscape 32
Competitive positioning of the top 10 companies 32
Exposure to US generics market 35
Comparative analysis of the top 10 companies 36
Trends 37
Increasing participation of innovator companies in Indian pharmaceutical space 37
Pharmaceutical companies making inroads into rural India 38
Shifting focus towards Japanese generics market 39
Growing prevalence of lifestyle diseases 40
Expanding alliances in biopharmaceuticals 41
Chapter 3 Cipla 46
Summary 46
Company overview 47
Marketed products 47
Therapeutic focus 49
Research and development 49
Growth strategies 50
Expanding in international markets through alliances and partnerships 50
Expanding capabilities 50
Growing in the US generics market 51
Acquisitions and divestments 51
SWOT analysis 52
Chapter 4 Ranbaxy 54
Summary 54
Company overview 55
Marketed products 56
Therapeutic focus 56
Research and development 57
Growth strategies 58
Rebuilding business in the US market 58
Shifting focus towards complex products in the US 58
Monetizing the FTF opportunities in the US 58
Improving penetration in emerging markets 59
Strengthening management involvement in Ranbaxy 59
Acquisitions and divestments 60
SWOT analysis 61
Chapter 5 GSK (India) 64
Summary 64
Company overview 65
Marketed products 66
Therapeutic focus 66
Research and development 67
Growth strategies 68
Augmenting product portfolio in India 68
Leveraging its parent company’s product portfolio 68
In-licensing products 69
Expanding rural presence and hospital sales 69
Acquisitions and divestments 70
SWOT analysis 71
Chapter 6 Piramal Healthcare 74
Summary 74
Company overview 75
Marketed products 75
Therapeutic focus 77
Research and development 77
Growth strategies 78
Capitalize on contract manufacturing opportunities 78
Growing business through alliances and partnerships 78
Acquisitions and divestments 79
SWOT analysis 81
Chapter 7 Zydus Cadila 84
Summary 84
Company overview 85
Marketed products 86
Therapeutic focus 86
Research and development 87
Growth strategies 88
Alliances fostering growth in international generics markets 88
Sustaining revenue growth in Indian formulation business 89

Browse complete The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses Report

Browse all Banking and Financial Services Market Research Reports

Browse all Datamonitor Market Research Reports

Browse all Newly Published Market Research Reports

Related Reports:
The Natural Gas Power Generation Technologies Market Outlook: Market overview, capacity, generation, 

new developments and the future outlook

Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of legal, productivity, and quality control issues

The Western European Gas Market Outlook 2010: Country profiles of supply, demand, regulation and infrastructure

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact: 
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/